Clinical trials: Pre-capillary Pulmonary Hypertension
Hypertension, Pulmonary
A Study of Sotatercept for the Treatment of Cpc-PH Due to HFpEF (MK-7962-007/A011-16)
This is a Phase 2, double-blind, randomized, placebo-controlled study to evaluate the efficacy and safety of sotatercept versus placebo in adults with Cpc-PH due to HFpEF.
- Trial name
- CADENCE (NCT04945460)
- Testing
- Sotatercept 0.3 mg/kg, Sotatercept 0.3 mg/kg escalating to 0.7 mg/kg
- Where
- 119 sites in United States, Belgium and 10 more
- Volunteers
- 165 people
- Sponsor
- Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USA
Pulmonary Hypertension
Clinical Study to Evaluate the Safety and Tolerability of Macitentan in Subjects With Combined Pre- and Post-capillary Pulmonary Hypertension (CpcPH) Due to Left Ventricular Dysfunction
Study to evaluate if macitentan is safe and tolerable enough to be used for treatment of subjects with combined pre- and post-capillary pulmonary hypertension (CpcPH) due to left ventricular dysfunction.
- Trial name
- MELODY-1 (NCT02070991)
- Testing
- Macitentan
- Where
- 32 sites in United States, Austria and 9 more
- Volunteers
- 63 people
- Sponsor
- Actelion
Precapillary Pulmonary Hypertension
The Role of Trimetazidine on Right Ventricle Function in Pulmonary Arterial Hypertension
The study will evaluate the effect of trimetazidine versus placebo in addition to standard pulmonary arterial hypertension regime on right ventricular function in pulmonary arterial hypertension patients.
- Trial name
- TRIMETA-PH (NCT03273387)
- Testing
- Trimetazidine
- Where
- Indonesia
- Volunteers
- 26 people
- Sponsor
- Universitas Indonesia